| |
|
|
|
|
|
 |
| |
|
³ë¹ÙƼ½ºÇ÷ç¿À·¹¼¼ÀÎÁÖ(Ç÷ç¿À·¹¼¼ÀÎ) Novartis Fluorescein Inj.
|
Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ(41)
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653600060[E01631341]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/5ml/¾ÚÇÃ(2016.10.01)(ÇöÀç¾à°¡)
\7,017 ¿ø/5ml/¾ÚÇÃ(2016.03.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¾îµÎ¿î ÁÖȲ»öÀÇ ¾×ÀÌ µç ¾ÚÇà [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1¾ÚÇÃ(5¹Ð¸®¸®ÅÍ) X Á¦Á¶¿ø |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 5¹Ð¸®¸®ÅÍ |
10 ¾ÚÇÃ |
¾ÚÇÃ |
8806536000604 |
8806536000628 |
|
| 5¹Ð¸®¸®ÅÍ |
1 ¾ÚÇÃ |
¾ÚÇÃ |
8806536000604 |
8806536000611 |
|
|
| ÁÖ¼ººÐÄÚµå |
161101BIJ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Ç÷°üÁ¶¿µ, Ç÷°ü°Ë»ç µîÀÇ Áø´Ü¿ë
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¾ÚÇÿ¡ µç ¿ë¾×À» ÁÖÀüÇ÷°ü¿¡ ½Å¼ÓÈ÷ ÁÖÀÔÇÑ´Ù.
9-14ÃÊ ³»¿¡ ¸Á¸·, ¸Æ¶ô¸·ÀÇ Ç÷°üÀÇ ¹ß±¤À» ÀϹݰ˾ȰæÀ¸·Î °üÂûÇÒ ¼ö ÀÖ´Ù. Àẹ¼ºÀÇ ¾Ë·¯Áö°¡ ÀǽɵǸé ÁÖ»ç Àü¿¡ ÇǺιÝÀÀ °Ë»ç¸¦ ÇàÇÑ´Ù. Áï, ÇÇÇÏ¿¡ 0.05¹Ð¸®¸®Å͸¦ ÁÖ»çÇÑ ÈÄ¿¡ 30-60ºÐ µ¿¾ÈÀÇ ¹ÝÀÀÀ» Æò°¡ÇÑ´Ù. ÀÀ±Þóġ¸¦ À§ÇÏ¿©
01% ¿¡Çdz×ÇÁ¸° ÁÖ»ç¾×À̳ª Ç×È÷½ºÅ¸¹ÎÁ¦, »ê¼Ò¸¦ »óºñÇØ¾ß ÇÑ´Ù.
- ¼ºÀÎ : 500mg ´Üȸ Á¤¸Æ Åõ¿© (1¾ÚÇà 5mL)
- ¼Ò¾Æ : üÁß 10ÆÄ¿îµå´ç 35¹Ð¸®±×¶÷ ±âÁØÀ¸·Î Åõ¿©(7.7mg/kg)
|
| ±Ý±â |
- ´ÙÀ½ ȯÀÚ¿¡´Â Åõ¿©ÇÏÁö ¸» °Í
1) ÀÌ ¾à ¶Ç´Â ÀÌ ¾àÀÇ ±¸¼º¼ººÐ¿¡ °ú¹Î¼ºÀÌ Àִ ȯÀÚ
2) ÀÌ ¾àÀÇ ÁöÁÖ¸·ÇÏ, °æ(Áú)¸·³», ¶Ç´Â µ¿¸Æ³» ÁÖ»ç
3) ÁßÁõÀÇ ÁßÃ߽Űæ°è Àå¾Ö, °¨¿°Áõ, ¼øÈ¯±â°è ÁúȯÀÌ Àִ ȯÀÚ
4) Àü½Å¼è¾à ȯÀÚ
- ´ÙÀ½ ȯÀÚ¿¡°Ô´Â Åõ¿©ÇÏÁö ¾Ê´Â °ÍÀ» ¿øÄ¢À¸·Î ÇϵÇ, ƯÈ÷ ÇÊ¿ä·Î ÇÏ´Â °æ¿ì¿¡´Â ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
1) ÁßÁõÀÇ µ¿¸Æ°æÈÁõ, °¥»ö ¼¼Æ÷Á¾ ȤÀº ½ÉÁúȯ ÀǽÉÀÌ Àִ ȯÀÚ (Ç÷¾ÐÀÇ ±Þ¼ÓÇÑ º¯µ¿À» ÀÏÀ¸Å³ ¿ì·Á°¡ ÀÖ´Ù.)
2) °í·ÉÀÚ(¿ë·®À» Á¶ÀýÇÒ ÇÊ¿ä ¾øÀ½)
3) ÀÓ»êºÎ
|
| ½ÅÁßÅõ¿© |
1) °£Àå¾Ö ¶Ç´Â ½ÅÀå¾Ö°¡ Àִ ȯÀÚ
2) ÁßÁõÀÇ °íÇ÷¾ÐÁõ ȯÀÚ
3) ÁßÁõ õ½Ä, Æó±âÁ¾, ½ÉºÎÀü, È£Èí±â °¨¿°ÁõÀÌ Àִ ȯÀÚ
4) ¾çÄ£, ÇüÁ¦¿¡ ±â°üÁö õ½Ä, ´ã¸¶Áø, Á¢Ã˼º ÇǺο°, ¾àÁ¦ °ú¹ÎÁõ, ¾ÆÅäÇÇ, ±âŸ ¾Ë·¯Áö Áúȯ µîÀÇ ±â¿Õ·Â ¶Ç´Â ¼ÒÀÎÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
¾Æ·¡´Â Àڹߺ¸°í ¹× ¹®ÇåÀ» ÅëÇØ Á¢¼öµÈ post-marketing¿¡¼ ³ªÅ¸³ ÀÌ»ó¹ÝÀÀÀ¸·Î, º¸°íµÈ Àα¸ÀÇ Å©±â¸¦ ¾Ë ¼ö ¾ø°í µû¶ó¼ ±× ºóµµ¸¦ ¾Ë ¼ö ¾ø´Ù. ÀÌ»ó¹ÝÀÀÀº ±â°üº° ¹× ÁßÁõµµº°·Î ³ª¿ÇÑ´Ù (ÁßÁõµµ°¡ ³ôÀº ¼ø¼¿¡¼ ³·Àº ¼ø¼·Î ³ª¿).
°¡Àå ÈçÈ÷ º¸°íµÇ´Â ÀÌ»ó ¹ÝÀÀÀº ¿À½É ¹× ±¸ÅäÀÌ´Ù.
1) ¸é¿ª°è ÀÌ»ó: ÀÌ ¾àÀ» Åõ¿©¹ÞÀº ȯÀÚ¿¡¼ µå¹°°Ô ¾Æ³ªÇʶô½Ã½º/À¯»ç¾Æ³ªÇʶô½Ã½º ¼îÅ© °ú¹Î ¹ÝÀÀÀÌ º¸°íµÇ¾ú´Âµ¥ ±× Áß ¸î¸î Ä¡¸íÀûÀÎ °á°ú°¡ ³ªÅ¸³µ´Ù.
2) ½Å°æ°è ÀÌ»ó: ³úÇ÷°ü »ç°í, °æ·Ã, ½Ç½Å, µÎÅë, ¾îÁö·¯¿ò, °¨°¢ÀÌ»ó
3) ½ÉÀå Áúȯ: ½ÉÀåÁ¤Áö, ±Þ¼º½É±Ù°æ»ö, ¼îÅ©
4) Ç÷°ü Áúȯ: ÀúÇ÷¾Ð, ¾È¸éÈ«Á¶
5) È£Èí±â・ÈäºÎ・Á¾°Ý Áúȯ: È£Èí°ï¶õ, ÈĵκÎÁ¾, ±â°üÁö°æ·Ã
6) À§Àå°ü Áúȯ: ¿À½É, ±¸Åä
7) ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ Áúȯ: ÇǺο°, µÎµå·¯±â, ¼Ò¾çÁõ, ÀÌ ¾à Åõ¿© ÈÄ ÇǺΰ¡ ÀϽÃÀûÀ¸·Î 12½Ã°£±îÁö ³ë¶õ»öÀ¸·Î º¯»öµÉ ¼ö ÀÖ´Ù.
8) ½ÅÀå ¹× ¿ä·Î°è Áúȯ: ÀÌ ¾à Åõ¿© ÈÄ 24-36½Ã°£ µ¿¾ÈÀº ¹àÀº ³ë¶õ»ö ´¢°¡ ¹è¼³µÉ ¼ö ÀÖ´Ù.
9) Àü½Å Áúȯ ¹× Åõ¿©ºÎÀ§ »óÅÂ: ÁÖ»çºÎÀ§ÀÇ Ç÷ÀüÁ¤¸Æ¿°, ½É°¢ÇÑ ÅëÁõÀ» ÀÏÀ¸Å°°í Á¶Á÷±«»ç±îÁö ÀÏÀ¸Å³ ¼ö ÀÖ´Â Ç÷°ü ¹Û À¯Ãâ, ÈäÅë, ¿ÀÇÑ, ±Çۨ
|
| »óÈ£ÀÛ¿ë |
1) º£Å¸ -Â÷´ÜÁ¦ÀÇ beta-receptor ¹æÇØ ÀÛ¿ëÀ¸·Î ¾Æ³ªÇʶô½Ã½º/À¯»ç¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÌ ´õ ½É°¢ÇØÁú ¼ö ÀÖ´Ù.
2) ÀÌ ¾à Åõ¿© ÈÄ 3-4ÀÏ µ¿¾È Çü±¤ÀÌ Ç÷¾× ¹× ´¢ÀÇ ÆÄ¶ó¹ÌÅÍ ºÐ¼®À» ¹æÇØÇÒ ¼ö ÀÖ´Ù. Çü±¤Æí±¤¸é¿ªºÐ¼®¹ý¿¡ ±âÃÊÇÑ ºÐ¼®±â¸¦ »ç¿ëÇÏ¿© µð°í½Å°ú ÄÚ¸£Æ¼¼ÖÀÇ Ç÷û ³óµµ¸¦ °áÁ¤Çϴµ¥ ÀÖ¾î¼ ÀÌ ¾àÀÇ Àü½Å ³óµµ°¡ ¹æÇذ¡ µÇ¾ú´ø °ÇÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù. µû¶ó¼ ÀûÁ¤ ¾à¹° ³óµµÀÇ ¹üÀ§°¡ Á¼Àº ¾à¹°ÀÇ Ä¡·á ¸ð´ÏÅ͸µ ½Ã ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù.
3) À¯±âÀ½ÀÌ¿ÂÀÇ ´Éµ¿ ¼ö¼ÛÀ» ÀúÇØÇÏ´Â ¾à¹°(¿¹¸¦ µé¾î, ÇÁ·Îº£³×½Ãµå)Àº ÀÌ ¾àÀÇ Àü½Å ÇÁ·ÎÇÊ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Ù.
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Fluorescein¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Fluorescein sodium is used extensively as a diagnostic tool in the field of ophthalmology. Fluorescein is a fluorescent compound or fluorophore having a maximum absorbance of 494 m and an emission maximum of 521 nm. The yellowish-green fluorescence of the compound can be used to demarcate the vascular area under observation, distinguishing it from adjacent areas. It is applied topically in the form of a drop or it can be injected intravenously to produce a fluorescein angiogram. Topical fluorescein is a useful tool in the diagnosis of corneal abrasions, corneal ulcers, herpetic corneal infections, and dry eye. Fluorescein angiography is used to diagnose and categorize macular degeneration, diabetic retinopathy, inflammatory intraocular conditions, and intraocular tumors.
|
| Pharmacology |
Fluorescein¿¡ ´ëÇÑ Pharmacology Á¤º¸ Not Available
|
| Protein Binding |
Fluorescein¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 85%
|
| Half-life |
Fluorescein¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Fluorescein¿¡ ´ëÇÑ Absorption Á¤º¸ Rapidly distributed
|
| Pharmacokinetics |
Fluorescein SodiumÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : ¾ÈÇ÷°üÁ¶¿µ¼ú : ÁÖ»ç : 6-15ÃÊ
- ºÐÆ÷¿ëÀû : 0.5 L/kg
- ´Ü¹é°áÇÕ : ¾à 80-90%
- ´ë»ç : °£´ë»ç
- ¹Ý°¨±â : 1½Ã°£ ¹Ì¸¸
- ¼Ò½Ç : 99% ÀÌ»óÀÌ ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Fluorescein¿¡ ´ëÇÑ Description Á¤º¸ A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
|
| Drug Category |
Fluorescein¿¡ ´ëÇÑ Drug_Category Á¤º¸ Contrast MediaFluorescent Dyes
|
| Smiles String Canonical |
Fluorescein¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ OC1=CC2=C(C=C1)C1(OC(=O)C3=CC=CC=C13)C1=C(O2)C=C(O)C=C1
|
| Smiles String Isomeric |
Fluorescein¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ OC1=CC2=C(C=C1)C1(OC(=O)C3=CC=CC=C13)C1=C(O2)C=C(O)C=C1
|
| InChI Identifier |
Fluorescein¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
|
| Chemical IUPAC Name |
Fluorescein¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-11-03
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|